Please assess the completion status of the following clinical trial:

Trial Title: Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease (BEST)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years of older~* Angiographically confirmed multivessel CAD \[critical (\>70%) lesions in at least two major epicardial vessels and in at least two separate coronary artery territories (LAD, LCX, RCA)\] and amenable to either PCI or CABG.~* Indication for revascularization based upon symptoms of angina and/or objective evidence of myocardial ischemia~* Geographically accessible and willing to come in for required study visits~* Signed informed consent.~Exclusion Criteria:~* Severe congestive heart failure (class III or IV according to NYHA, or pulmonary edema) at the time of enrollment.~* Planned simultaneous surgical procedure unrelated to coronary revascularization (e.g. valve repair/replacement, aneurysmectomy, carotid endarterectomy or carotid stent).~* In-stent restenosis of a target vessel~* Prior CABG surgery~* Prior PCI with stent implantation within 1 year~* Two or more chronic total occlusions in major coronary territories~* Acute ST-elevation MI(Q-wave) within 72 hours prior to enrollment requiring revascularization~* Abnormal creatine kinase (CK \> 2x normal) and/or abnormal CK-MB levels and/or elevated Troponin levels at time of randomization~* Previous stroke within 6 months or patients with stroke at more than 6 months with significant residual neurologic involvement, as reflected in a Rankin Score \> 1~* Dementia with a Mini Mental Status Examination (MMSE) score of ≤ 20~* Extra-cardiac illness that is expected to limit survival to less than 2 years; e.g. oxygen-dependent chronic obstructive pulmonary disease, active hepatitis or significant hepatic failure, severe renal disease.~* Prior history of significant bleeding (within the previous 6 months) that might be expected to occur during CABG or PCI/DES related anticoagulation.~* Contraindication either CABG or PCI/DES because of a coexisting clinical condition~* Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis~* Intolerance or contraindication to aspirin or both clopidogrel and ticlopidine~* Suspected pregnancy. A pregnancy test (urine or serum) will be administered prerandomization to all women not clearly menopausal~* Concurrent enrollment in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- everolimus-eluting stent (Type: EXPERIMENTAL): everolimus-eluting stent
- coronary artery bypass graft surgery (Type: ACTIVE_COMPARATOR): coronary artery bypass graft surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).